Morphosys AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
MorphoSys AG Reaffirms FY 2013 Guidance
MorphoSys AG re-confirmed its guidance for fiscal 2013. The Group expects revenues of EUR48 million to EUR 52 million and anticipates an EBIT in the range of EUR-18 to EUR-22 million in 2013. Total operating expenses will amount to EUR70 million to EUR74 million, of which EUR32 million to EUR37 million represent investments in proprietary products and technologies. Additional income from an out-licensing deal in 2013, which is not included in the current guidance, could lead to out-performance of the guidance.
- Share this
- Digg this